NAME:               Adam Telerman
                                   
ADDRESS:    
                        Tumor reversion Lab
INSERM U981
Institut Gustave Roussy
Bâtiment B2M
114 rue Édouard-Vaillant
94805 Villejuif
France

                        email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.tumor-reversion.org
Phone lab: +33 1 42 11 42 11 ext. 3258
Office: +33 1 42 11 42 11 ext. 3882

BORN: June 15, 1954

CITIZENSHIP: Belgian, permanent resident in Paris, France

CIVIL STATUS: Married, two children

DEGREES AND EDUCATION:  M.D., Ph.D.
           
                      - Medical School: 7 year program. Free University of Brussels
                        (June 1980). Cum Laude
                      - Specialist in Internal Medicine and Hematology/Oncology 
                        Free University of Brussels (June 1985)
                      - Professorship and Ph.D. thesis (May 1989): Agrégé de l'Enseignement Supérieur
                        Free University of Brussels

POSITIONS:

1. Director of Research (CNRS), INSERM U981, Institut Gustave Roussy (2014-present)
Biology, Genetics and Pharmacology of Tumor reversion

2. Director of Research (CNRS), LBPA, UMR 8113, Ecole Normale Supérieure Cachan, France (2007-2013)
Genetics and epigenetics of Tumor reversion, cellular reprogramming of cancer cells

3. Member / Short-Term Visitor,
Systems Biology, School of Natural Sciences, Institute for Advanced Study, Princeton, USA (2006)

4. Director, Cancer Research, Molecular Engines Laboratories, Paris, France (2000- 2006)
Founder Molecular Engines Laboratories (2000)
Molecular and functional characterization of the tumor reversion pathways
Biological models and genes of tumor reversion
Conditional knock out mice for 3 genes
Crystal structure of target proteins
Drug discovery with one pharmaceutical compound in a phase I/II clinical trial in AML

5. Director, Cancer Genetics Program. Fondation Jean Dausset – CEPH, Paris, France (1994-2000)
Biological models and genes of tumor reversion
Molecular characterization of the tumor reversion pathways

6. Professeur Agrégé de l'Enseignement Supérieur
(Association Against Cancer)  (1989-1994)
Institute of Interdisciplinary Research, Faculty of Medicine. Free University of Brussels
Oncogenes and tumor suppressor genes in human leukemias. Initiation of research on biological models of tumor reversion
       
7. Senior Investigator
(Chargé de Recherche au Fonds National de la Recherche Scientifique) (1987-1989).
Institute of Interdisciplinary Research, Faculty of Medicine. Free University of Brussels
Oncogenes in human leukemias

8. EMBO long-term postdoctoral fellow (1985-1987)

Department of Chemical Immunology,
The Weizmann Institute of Science, Rehovot, Israel
Oncogenes in human leukemias

9. Fulbright Fellow (1983-1984)

Memorial Sloan-Kettering Cancer Center, New York (Professor C.D. Platsoucas)
Research on the association of CD3-T cell antigen receptor, T-T cell hybridomas,
Tumor Necrosis Factor

10. Research during training in Internal Medicine

a) Faculty of Medicine (Professor P. Galand),
Department of Immunology and Hôpital Erasme, Free University of Brussels (1984-1985)
Endocytosis of T-cell receptors, T cell activation
b) Department of General Chemistry, Free University of Brussels (Professor A.G. Schnek, J-P Prieels) (1983). Research on the biochemistry of iron binding molecules (lactoferrin). Analysis of glycoproteins of human T and B leukemic cell lines. Analysis of specific enzyme activities of leukemic B and T lymphocytes (Galactosyltransferase, fucosyltransferase, sialyltransferase)

11. Research during medical studies
Laboratory of Experimental Hematology (Professor P. Stryckmans) (1978-1981)
Institut Jules Bordet, Free University of Brussels.
Research on committed stem cells of the eosinophilic lineage (CFUeo)
Investigations on lactoferrin as a regulator of hematopoiesis

TEACHING:

Molecular biology and genetics of cancer (ENS Cachan, M1 de Cancérologie and Ecole doctorale de cancérologie)

HOSPITAL EXPERIENCE IN THE UNITED STATES:

- Memorial Sloan-Kettering Cancer Center, New York. Department of Hematology-Lymphoma. Fulbright
   Fellow, 1 year (1983-1984)
- Mount Sinai School of Medicine. Department of Hematology (summer-fall rotation 1978)
- Harvard Medical School, Peter Bent Brigham Hospital, Department of Hematology (summer rotation 1979)
- Harvard Medical School, Beth Israel Hospital, Department of Hematology (summer-fall rotation 1979 and 1980)

TRAINING IN INTERNAL MEDICINE:

-1980-81: Institut Jules Bordet, Free University of Brussels
-1981-83: Hôpital de Saint Gilles, Free University of Brussels
-1983-84: Memorial Sloan-Kettering Cancer Center, New York, USA
-1984-85: Hôpital Erasme, Free University of Brussels

E.C.F.M.G. CERTIFICATE: (1979)

HONORS, FELLOWSHIPS AND GRANTS:

- LabEx LERMIT (2011)
- Agence Nationale de la Recherche Programme Blanc 680,000 € (2009-2012)
- Association Sclérose Tubéreuse de Bourneville (2010-2011)
- 7th Framework Programme, Conticanet, Network of excellence, European Union 220,000 € (18 months: 2009-2010)

- 6th Framework Programme, Conticanet, Network of excellence, European Union 220,000 € (18 months: March 2008-2009)
- Conticanet, Network of excellence, European Union 220,000 € (18 months: March 2008-2009)
- European Community Grant: EUREKA 1,050,000 € (2003-2004)
- ANVAR, Ministry of Health 1,100,000 € (2000-2004)
- Crédit Impôt Recherche 2,700,000 € (2000-2004)
- Fondation Jean Dausset 6,000,000 € (1994-2000)
- Fonds National de la Recherche Scientifique (FNRS) (1987-1995)
- Association Against Cancer (1989-1994)
- FNRS: Chargé de Recherches (1987-1989)
- Grant: Fondation Emile Defay (1989)
- Grant: Commission crédits de recherche U.L.B. (1988)
- EMBO Long-Term postdoctoral fellowship (1985-87)
- Fulbright Award for Research. Commission of Education, Congress of the USA (1983-84)
- Recipient of studies award in Medicine, Belgian Ministry of Health (1973-80)

PRIVATE INVESTMENTS: 17,100,000 € (2000-2004)
-HBM BioVentures AG (Switzerland)
-3i (Germany)
-VENTECH (France)
-ODYSSEE VENTURE (France)
-Technologieholdung (Germany)
-NMT Management AG (Switzerland)

LANGUAGES: French, English, Dutch, Polish, German, Italian, Hebrew